NEW YORK (TheStreet) -- Shares of Exact Sciences Corp. (EXAS) - Get Report are decreasing by 2.04% to $5.75 on heavy volume in Thursday afternoon trading, after the company reported its 2015 fourth quarter results.
Before yesterday's market open, the Madison, WI-based molecular diagnostics company posted a loss of 41 cents per share, which was narrower than the loss of 48 cents per share analysts' were expecting.
Revenue for the period was $14.4 million, missing Wall Street's estimates of $14.82 million.
For the full year, the company said its loss widened to $157.8 million, or $1.71 per share. Last year, it posted a loss of $100 million, or $1.25 per share.
Additionally, Jefferies lowered its price target on the stock to $13 from $15 and maintained its "buy" rating this morning.
"The current issues appear more seasonal than structural, in our view. Commercial payor coverage remains the central gating factor, but incremental progress on-boarding Anthem (ANTM) is positive & EXAS appears committed to preserving its balance sheet in the interim while it lobbies for broader reimbursement," the firm said in an analyst note.
Exact Sciences is focused on the early detection and prevention of colorectal cancer.
About 2.93 million of the company's shares were traded by this afternoon versus its average volume of 1.97 million shares per day.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by a number of negative factors, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: EXAS